157 related articles for article (PubMed ID: 25846744)
1. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
3. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
4. The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
Xing L; Lv HT; Liu SG; Wang WB; Zhang TF; Liu JH; Bian W
Scand J Gastroenterol; 2021 Aug; 56(8):914-919. PubMed ID: 34165373
[TBL] [Abstract][Full Text] [Related]
5. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.
Guo ZJ; Yang L; Qian F; Wang YX; Yu X; Ji CD; Cui W; Xiang DF; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Oncotarget; 2016 Apr; 7(15):20999-1012. PubMed ID: 27007162
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Redjal N; Chan JA; Segal RA; Kung AL
Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
[TBL] [Abstract][Full Text] [Related]
13. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
[TBL] [Abstract][Full Text] [Related]
15. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
Wang J; Tannous BA; Poznansky MC; Chen H
Pharmacol Res; 2020 Sep; 159():105010. PubMed ID: 32544428
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma.
Jeong WJ; Choi IJ; Park MW; An SY; Jeon EH; Paik JH; Sung MW; Ahn SH
J Clin Pathol; 2014 Nov; 67(11):992-8. PubMed ID: 25118295
[TBL] [Abstract][Full Text] [Related]
19. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
20. A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.
Ablett MP; O'Brien CS; Sims AH; Farnie G; Clarke RB
Oncotarget; 2014 Feb; 5(3):599-612. PubMed ID: 24583601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
